Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Ulas D. Bayraktar, MD

Thyroid Cancer

New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer

Ulas D. Bayraktar, MD

Bladder Cancer

New Indication: Erdafitinib in Advanced FGFR Altered Urothelial Cancer

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Perioperative Durvalumab for NSCLC

Ulas D. Bayraktar, MD

Mesothelioma

New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma

Ulas D. Bayraktar, MD

Colorectal Cancer

New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer

Ulas D. Bayraktar, MD

Melanoma

New Drug: Relatlimab and Nivolumab for Advanced Melanoma

Ulas D. Bayraktar, MD

Breast Cancer

New Reference: Pembrolizumab in Triple-Negative Breast Cancer

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

Investigator-initiated, open-label, single-arm, multi-institutional, phase II trial (TAB) Adult patients with HER2-positive, treatment-naïve BTCs Trastuzumab + Gemcitabine + Cispl

Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Multi-center, phase 2 nonrandomized clinical trial (UNICORN) Previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion muta

New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer

Phase 3, randomized trial (LIBRETTO-531) RET mutant, unresectable, locally advanced or metastatic medullary thyroid cancer and no history of treatment with kinase inhibitors Selpe

New Indication: Erdafitinib in Advanced FGFR Altered Urothelial Cancer

Phase 3, randomized trial, multicenter ttrial ( THOR) FGFR-altered metastatic urothelial carcinoma whose disease progressed after one or two previous treatments that included an a

Non-Small Cell Lung Cancer

New Indication: Perioperative Durvalumab for NSCLC

A Phase III, double-blind, placebo-controlled, multicenter, international Study (AEGEAN) Resectable Stages IIA to IIIB Non-small Cell Lung Cancer Perioperative Durvalumab + Chemot

New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma

Single-arm, single-centre, phase 2 study (PEMMELA) Pleural mesothelioma, who progressed after chemotherapy Pembrolizumab + Lenvatinib (n=38)

Colorectal Cancer

New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer

Phase 3, multicenter, open-label, randomized, active-controlled trial (CODEBREAK 300) KRAS G12 C mutant metatatic colorectal cancer, were disease progression or recurrence after r

New Drug: Relatlimab and Nivolumab for Advanced Melanoma

Double-blind, randomized Phase II-III trial Untreated metastatic or unresectable melanoma Relatlimab and nivolumab vs nivolumab alone

New Reference: Pembrolizumab in Triple-Negative Breast Cancer

Randomized, double-blind, placebo-controlled trial (KEYNOTE-522) Previously untreated stage II or III triple-negative breast cancer Neoadjuvant/adjuvant pembrolizumab (n=784) or pl

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag